Recent Finacing
Recent Raise
AsclepiX Therapeutics is a Baltimore clinical-stage biopharma using computational biology to discover peptide regulators for retinal vascular diseases; developing AXT107, an intravitreal peptide depot targeting VEGF and activating Tie2.
